# A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

> **NCT00681538** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 572 (actual)

## Conditions studied

- Spasticity
- Multiple Sclerosis

## Interventions

- **DRUG:** Sativex®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00681538
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681538, "A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00681538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*